ArticleBone & joint research2025
Complex network model reveals the positive effect of melatonin on bone parameters in rats with induced hypoestrogenism.
Article in Bone & joint research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Melatonin (MEL) has been investigated as a strategy to prevent bone loss related to oestrogen deficiency. However, its systemic impact on multiple bone properties is not completely established. This study evaluated the effects of chronic MEL administration on bone parameters commonly compromised by hypoestrogenism, using complex network analyses as an innovative approach to integrate bone outcomes. Methods: A total of 40 female Wistar rats were allocated into four groups: control + vehicle (CG), ovariectomized + vehicle (OG), melatonin (MG), and ovariectomized + melatonin (MOG). OG and MOG underwent bilateral ovariectomy (OVX) at 15 weeks of age. One week later, animals received daily melatonin (MG and MOG, 10 mg.kg Results: Traditional analyses confirmed that OVX impaired bone health, while MEL treatment improved mechanical strength and preserved bone properties. Overall, treated animals exhibited values closer to CG than to OG and complex network analyses elucidated the physiological adjustments in response to interventions. Centrality metrics indicated that MEL modulated parameters to enhance the bone's load-bearing capacity, while biophysical aspects were more central in other groups and became key connectors in MG with Betweenness centrality. Conclusion: Our results suggest that MEL administration positively influences bone mechanics under different stress conditions and prevents deterioration related to osteometabolic disorders caused by OVX. Complex network analyses highlighted biomechanical variables as central in groups treated with MEL, while biophysical variables acted as key connectors. These findings provide an integrative understanding of the physiological adaptations promoted by MEL to maintain bone strength, through reorganization of the functional importance of biomechanical and biophysical parameters under hypoestrogenism conditions over 12 weeks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.